Company Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.
The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.
It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies.
The company was incorporated in 2016 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 587 |
| CEO | Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. |
Contact Details
Address: 1800 Owens Street, Suite 900 San Francisco, California 94158 United States | |
| Phone | 415-906-4324 |
| Website | vir.bio |
Stock Details
| Ticker Symbol | VIR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001706431 |
| CUSIP Number | 92764N102 |
| ISIN Number | US92764N1028 |
| Employer ID | 81-2730369 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ann M. Hanly Ph.D. | Executive Vice President and Chief Technology Officer |
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | Chief Executive Officer and Director |
| Dr. Klaus Frueh Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Lawrence Corey M.D. | Co-Founder and Scientific Advisor |
| Dr. Louis J. Picker M.D. | Co-Founder and Scientific Advisor |
| Sung H. Lee | Executive Vice President and Chief Financial Officer |
| Dr. Jennifer Eileen Towne Ph.D. | Executive Vice President and Chief Scientific Officer |
| Heather Rowe Armstrong | Vice President of Investor Relations |
| Vanina De Verneuil J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Cara Miller | Vice President of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | ARS | Filing |
| Apr 19, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 19, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2024 | 8-K | Current Report |
| Apr 4, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |
| Feb 26, 2024 | 144 | Filing |
| Feb 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 26, 2024 | 10-K | Annual Report |
| Feb 22, 2024 | 8-K | Current Report |